List view / Grid view
Experimental Parkinson’s drug PRI-101 has shown promising preclinical results, effectively targeting and disassembling toxic α-synuclein protein aggregates that drive neurodegeneration.
Automation is helping drug discovery teams screen faster, cut costs and run complex assays at scale – but its real value lies in what happens next.
Experts from the World ADC Conference in London highlight how patient-centric, predictive preclinical tools and innovative ADC designs are improving safety, efficacy and clinical translation.
The UK has set out a strategy to replace animal testing, but delivering change will depend as much on regulation as on technology. Dr Emma Grange, Director of Science and Regulatory Affairs at Cruelty Free International, examines what the policy signals for research, drug discovery and safety assessment.
Northwestern scientists have grown human spinal cord organoids to test therapies that could reduce scarring and promote nerve regrowth in patients.
Scientists have developed an AI-enhanced imaging platform that enables non-invasive, label-free and longitudinal monitoring of cancer organoids and spheroids.
A push by the US Food and Drug Administration to phase out animal testing in drug development could improve efficiency and reduce animal suffering, but experts warn that moving too quickly may pose risks to patient safety.
Researchers have developed 3D human brain organoids that reveal how glioblastoma interacts with brain and immune cells, discovering hidden drivers of tumour invasion.
30 January 2026 | By Yokogawa
This webinar examines the design trade-offs and technical constraints involved in building a high-throughput robotic imaging pipeline for complex biological workflows.
Scientists have grown the first multi-regional “mini-stomach” in the lab, creating a new way to study rare genetic stomach diseases and help to develop new treatments for digestive conditions.
2026 is set to be a pivotal year for drug discovery, with advances in NAMs and evolving regulatory approaches promising faster, safer early drug development and accelerated delivery of therapies for patients with rare or unmet medical needs.
Researchers have developed vascularised human retinal organoids featuring the first fully functional light-signal pathways in lab-grown human retina models, opening new possibilities for studying eye disease and testing therapies.
Researchers have shown that applying magnetic forces to lab-grown human heart organoids enhances their maturation and vascular development, offering a more realistic model of early heart formation and the possibility of future cardiac therapies.
Life-saving HIV and cancer drugs can carry serious neurological risks, and new funding will help UMBC researchers discover how these medicines damage the brain – which could help to inform safer treatments.
A partnership between Atelerix and Cherry Biotech is enabling the shipping of complex biological models worldwide, using hydrogel preservation technology to eliminate cold-chain logistics.
